S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden's Plan to Confiscate Your Cash? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Biden's Plan to Confiscate Your Cash? (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden's Plan to Confiscate Your Cash? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Biden's Plan to Confiscate Your Cash? (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden's Plan to Confiscate Your Cash? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Biden's Plan to Confiscate Your Cash? (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Biden's Plan to Confiscate Your Cash? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
Biden's Plan to Confiscate Your Cash? (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Will This Be the Worst U.S. Crisis Ever? (Ad)
NASDAQ:ISEE

IVERIC bio - ISEE Stock Forecast, Price & News

$13.63
+0.25 (+1.87%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.24
$13.90
50-Day Range
$9.12
$13.63
52-Week Range
$8.37
$19.34
Volume
2.06 million shs
Average Volume
1.79 million shs
Market Capitalization
$1.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.20

IVERIC bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
77.5% Upside
$24.20 Price Target
Short Interest
Healthy
5.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of IVERIC bio in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$240,500 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.49) to ($1.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

212th out of 1,108 stocks

Pharmaceutical Preparations Industry

88th out of 542 stocks

ISEE stock logo

About IVERIC bio (NASDAQ:ISEE) Stock

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Analyst Ratings Changes

Several research firms have commented on ISEE. Guggenheim started coverage on shares of IVERIC bio in a research note on Wednesday, June 8th. They set a "buy" rating and a $30.00 price objective for the company. UBS Group assumed coverage on IVERIC bio in a research note on Tuesday, August 2nd. They issued a "buy" rating and a $20.00 price objective for the company. Stifel Nicolaus boosted their target price on IVERIC bio from $22.00 to $28.00 in a report on Wednesday, May 4th. Morgan Stanley boosted their target price on IVERIC bio from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, July 7th. Finally, B. Riley initiated coverage on IVERIC bio in a research note on Thursday, May 12th. They set a "neutral" rating and a $12.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $24.20.

IVERIC bio Stock Performance

NASDAQ:ISEE opened at $13.38 on Wednesday. The firm has a 50-day simple moving average of $10.75 and a two-hundred day simple moving average of $13.20. The firm has a market cap of $1.58 billion, a P/E ratio of -10.97 and a beta of 1.52. IVERIC bio has a fifty-two week low of $8.37 and a fifty-two week high of $19.34.

IVERIC bio (NASDAQ:ISEE - Get Rating) last issued its quarterly earnings results on Tuesday, July 26th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). During the same quarter last year, the firm earned ($0.32) EPS. On average, equities research analysts predict that IVERIC bio will post -1.49 EPS for the current year.

Insider Activity

In other IVERIC bio news, Director Calvin W. Roberts acquired 25,000 shares of the stock in a transaction that occurred on Monday, June 13th. The stock was bought at an average cost of $9.62 per share, with a total value of $240,500.00. Following the completion of the purchase, the director now directly owns 32,500 shares in the company, valued at $312,650. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Calvin W. Roberts bought 25,000 shares of IVERIC bio stock in a transaction on Monday, June 13th. The stock was acquired at an average cost of $9.62 per share, for a total transaction of $240,500.00. Following the completion of the acquisition, the director now owns 32,500 shares of the company's stock, valued at approximately $312,650. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Christopher Paul Simms sold 12,272 shares of the business's stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $11.25, for a total transaction of $138,060.00. Following the completion of the transaction, the senior vice president now owns 28,547 shares of the company's stock, valued at $321,153.75. The disclosure for this sale can be found here. Insiders own 2.70% of the company's stock.

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Stock News Headlines

IVERIC bio, Inc. (NASDAQ:ISEE) SVP Sells $138,060.00 in Stock
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
What 5 Analyst Ratings Have To Say About IVERIC bio
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
Short Volatility Alert: IVERIC bio, Inc.
Expert Ratings for IVERIC bio
See More Headlines
Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Company Calendar

Last Earnings
7/26/2022
Today
8/11/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISEE
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.20
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+77.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-114,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.14 per share

Miscellaneous

Free Float
114,890,000
Market Cap
$1.61 billion
Optionable
Optionable
Beta
1.52














ISEE Stock - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ISEE shares.
View ISEE analyst ratings
or view top-rated stocks.

What is IVERIC bio's stock price forecast for 2022?

10 analysts have issued twelve-month price objectives for IVERIC bio's shares. Their ISEE share price forecasts range from $12.00 to $30.00. On average, they expect the company's stock price to reach $24.20 in the next twelve months. This suggests a possible upside of 77.5% from the stock's current price.
View analysts price targets for ISEE
or view top-rated stocks among Wall Street analysts.

How have ISEE shares performed in 2022?

IVERIC bio's stock was trading at $16.72 at the beginning of the year. Since then, ISEE shares have decreased by 18.5% and is now trading at $13.63.
View the best growth stocks for 2022 here
.

When is IVERIC bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ISEE earnings forecast
.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) released its earnings results on Tuesday, July, 26th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.10. During the same period last year, the firm earned ($0.32) earnings per share.

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by many different retail and institutional investors. Top institutional investors include Candriam S.C.A. (1.24%), Walleye Capital LLC (0.52%), Silverarc Capital Management LLC (0.00%), Connor Clark & Lunn Investment Management Ltd. (0.29%), Thornburg Investment Management Inc. (0.24%) and Frazier Life Sciences Management L.P. (0.14%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends
.

How do I buy shares of IVERIC bio?

Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $13.63.

How much money does IVERIC bio make?

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $1.61 billion. The company earns $-114,520,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (212) 845-8200 or via email at kathy.galante@ivericbio.com.

This page (NASDAQ:ISEE) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.